Evidence map›Paper›PMID 38734703›Full record

ArticleNPJ breast cancer2024

The deubiquitinating enzyme USP4 regulates BRCA1 stability and function.

Xueyuan Guo, Yanfang Ma, Ting Zhang, Runyu Liu, Fen Chang, Xingyue Yan, Tianyun Yu, Pengfei Wu, Qin Li, Luzheng Xu and 4 more

Abstract read
In one paragraph

Article in NPJ breast cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xueyuan Guo *Department of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.
Yanfang Ma *Department of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.
Ting ZhangDepartment of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.
Runyu LiuDepartment of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.
Fen ChangDepartment of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.
Xingyue YanDepartment of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.
Tianyun YuDepartment of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.
Pengfei WuDepartment of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.
Qin LiDepartment of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.
Luzheng XuCenter of Medical and Health Analysis, Peking University Health Science Center, Beijing, 100191, China.
Junyi DuanDepartment of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.
Li LiDepartment of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.
Yanrong SuThe Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA, 19111, USA.ORCID http://orcid.org/0000-0002-7059-5930
Genze ShaoDepartment of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China. gzshao@bjmu.edu.cn.ORCID http://orcid.org/0000-0002-4374-3969

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81772953National Natural Science Foundation of China (National Science Foundation of China) 81972477National Natural Science Foundation of China (National Science Foundation of China) 82172924National Science Foundation of China | Major Research Plan 2017YFA0503900
6 · The paper itself

Abstract

BRCA1 plays a suppressive role in breast tumorigenesis. Ubiquitin-dependent degradation is a common mechanism that regulates BRCA1 protein stability, and several ubiquitin ligases involved have been identified. However, the deubiquitinating enzyme for BRCA1 remains less defined. Here, we report that the deubiquitinase USP4 interacts with, deubiquitinates and stabilizes BRCA1, maintaining the protein level of BRCA1. USP4 knockdown results in a decreased BRCA1 protein level, impairment in homologous recombination mediated double-stranded break repair, and increased genome instability, and confers resistance to DNA damage-inducing agents and PARP inhibitors. Ectopic expression of USP4 stabilizes BRCA1 and reverse the effects caused by USP4 knockdown. Moreover, USP4 is low expressed in human breast cancer tissues and its low expression correlates with poorer survival of patients. Furthermore, we identified several loss-of-function mutations of USP4 in human gynecological cancers, the catalytic activity of which or their interaction with BRCA1 is disrupted. Together, we reveal that USP4 is a deubiquitinase for BRCA1. USP4 positively regulates the stability and function of BRCA1 through de-ubiquitination, and plays important role in the suppression of breast cancer.

Identifiers

PMID38734703
PMCPMC11088691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.